Yin Yang-1(YY-1) expression in idiopathic pulmonary fibrosis

Journal of Receptors and Signal Transduction

Volumn 31, Issue 2, 2011, Pages 188-191

  Margaritopoulos, Giorgos A ^a,b   Antoniou, Katerina M ^a,b,c   Soufla, Giannoula ^b   Vassalou, Evi ^b   Spandidos, Demetrios A ^b   Siafakas, Nikos M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

idiopathic pulmonary fibrosis; lung cancer; transcription factor; tumorigenesis; Yin Yang 1

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR YY1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG LAVAGE; PATHOGENESIS; PROTEIN EXPRESSION;

BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; GENE EXPRESSION REGULATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; YY1 TRANSCRIPTION FACTOR;

EID: 79952613236     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2011.557735     Document Type: Article

References (37)

1. Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle 2010, 9, 512-522.
2. Yakovleva T, Kolesnikova L, Vukojevic V, Gileva I, Tan-No K, Austen M, LÜscher B, Ekström TJ, Terenius L, Bakalkin G. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription. Biochem Biophys Res Commun 2004, 318, 615-624. (Pubitemid 38559074)
3. Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR, Shi Y. Yin Yang 1 is a negative regulator of p53. Cell 2004, 117, 859-872.
4. Riggs KJ, Saleque S, Wong KK, Merrell KT, Lee JS, Shi Y, Calame K. Yin-yang 1 activates the c-myc promoter. Mol Cell Biol 1993, 13, 7487-7495.
5. Shrivastava A, Yu J, Artandi S, Calame K. YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels. Proc Natl Acad Sci USA 1996, 93, 10638-10641. (Pubitemid 26333040)
6. Garbán HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 2001, 167, 75-81. (Pubitemid 32567763)
7. Brankin B, Skaar TC, Brotzman M, Trock B, Clarke R. Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol Biomarkers Prev 1998, 7, 1109-1115. (Pubitemid 29001667)
8. Beier UH, Görögh T. Implications of galactocerebrosidase and galactosylcerebroside metabolism in cancer cells. Int J Cancer 2005, 115, 6-10. (Pubitemid 40559664)
9. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007, 6, 1387-1399. (Pubitemid 46712002)
10. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005, 21, 4205-4208. (Pubitemid 41724298)
11. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006, 10, 1679-1688. (Pubitemid 46622139)
12. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004, 6, 775-781. (Pubitemid 38315167)
13. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980, 35, 496-499. (Pubitemid 10039553)
14. Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, Banba J. Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995, 45, 925-932. (Pubitemid 26036957)
15. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000, 161, 5-8.
16. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010, 35, 496-504.
17. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007, 353, 104-108. (Pubitemid 44958347)
18. Antoniou KM, Soufla G, Lymbouridou R, Economidou F, Lasithiotaki I, Manousakis M, Drositis I, Spandidos DA, Siafakas NM. Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. Connect Tissue Res 2010, 51, 71-80.
19. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009, 8, 1367-1372.
20. Antoniou KM, Margaritopoulos GA, Soufla G, Symvoulakis E, Vassalou E, Lymbouridou R, Samara KD, Kappou D, Spandidos DA, Siafakas NM. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recept Signal Transduct Res 2010, 30, 262-269.
21. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of cancer cells is maintained by EGFR independent of its inase activity. Cancer Cell 2008, 13, 385-393. (Pubitemid 351609444)
22. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, et al. Identifying genotype-dependent efficacy of single and combined PI3K and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009, 106, 18351-18356.
23. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14, 1351-1356.
24. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006, 3, 350-356. (Pubitemid 43845412)
25. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, Hara N. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996, 154, 477-483. (Pubitemid 26269122)
26. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 178, 729-737.
27. Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, Hu B, Choi YY, Ishikawa F, Phan SH. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest 2007, 117, 3800-3809. (Pubitemid 350224090)
28. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007, 104, 7552-7557. (Pubitemid 47185944)
29. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 2008, 266, 6-11.
30. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett 2005, 222, 1-10. (Pubitemid 40544841)
31. Königshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W, Eickelberg O. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS ONE 2008, 3, e2142.
32. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr; Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350, 125-133. (Pubitemid 38056223)
33. King TE, Behr J, Brown KK, du Bois RM, Raghu G. Bosentan use in idiopathic pulmonary fibrosis (IPF): results of the placebo controlled BUILD-1 study. Am J Respir Crit Care Med 2006, 3, A524.
34. Benito M, Diaz-Rubio E. Molecular biology in colorectal cancer. Clin Transl Oncol 2006, 8, 391-398.
35. Colebatch A, Hitchins M, Williams R, Meagher A, Hawkins NJ, Ward RL. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer 2006, 95, 1239-1243. (Pubitemid 44658489)
36. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2, e17.
37. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007, 30, 835-839. (Pubitemid 351194784)